Full Text Journal Articles by
Author Odd Erik Johansen

Advertisement

Find full text journal articles






Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.

Darren K McGuire, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, David Fitchett, Stefan D Anker, Stuart Pocock, Stefan Kaspers, Jyothis T George, Maximilian von Eynatten, Odd Erik Johansen, Waheed Jamal, Michaela Mattheus, Ulrich Elsasser, Stefan Hantel, Søren S Lund,

BACKGROUND:Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in the EMPA-REG OUTCOME trial. METHODS:The EMPA-REG OUTCOME trial was a randomised, double-blind, non-inferiority trial of patients (aged ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):949-959]

Cited: 0 times

View full text PDF listing >>



The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.

Ian J Neeland, Bjorn Eliasson, Takatoshi Kasai, Nikolaus Marx, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, Isabella Zwiener, Brian S Wojeck, Henry K Yaggi, Odd Erik Johansen, ,

OBJECTIVE:To explore the effects of empagliflozin on the incidence of obstructive sleep apnea (OSA) and its effects on metabolic, cardiovascular (CV), and renal outcomes among participants with or without OSA in the EMPA-REG OUTCOME trial. RESEARCH DESIGN AND METHODS:Participants with diabetes and CV disease were randomized to empagliflozin (10 and ... Read more >>

Diabetes Care (Diabetes care)
[2020, 43(12):3007-3015]

Cited: 0 times

View full text PDF listing >>



Advertisement

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial.

Mark A Espeland, Richard E Pratley, Julio Rosenstock, Takashi Kadowaki, Yutaka Seino, Bernard Zinman, Nikolaus Marx, Darren K McGuire, Knut Robert Andersen, Michaela Mattheus, Annett Keller, Maria Weber, Odd Erik Johansen,

AIMS:Safety is a key consideration for glucose-lowering agents for older people with type 2 diabetes, yet comparative data are limited. We compared the cardiovascular (CV) safety of linagliptin with glimepiride in older and younger participants in the CAROLINA trial in both pre-specified and post-hoc analyses. MATERIALS AND METHODS:People aged 40-85 years ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.

Silvio E Inzucchi, Melanie J Davies, Kamlesh Khunti, Prabhav Trivedi, Jyothis T George, Isabella Zwiener, Odd Erik Johansen, Naveed Sattar,

AIM:To investigate the association of different categories of baseline cardio-metabolic risk factors on the treatment effects of empagliflozin 10 and 25 mg when added as second-line therapy to metformin in patients with type 2 diabetes (T2D). MATERIALS AND METHODS:Patients aged 18 years or older with HbA1c 7.0%-10.0% were included. Analysis of covariance ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF.

Michael T Durheim, Anna-Maria Hoffmann-Vold, Tomas M Eagan, Arnt-Ove Hovden, May Brit Lund, Gisle Bjerke, Surinder S Birring, Trygve M Jonassen, Odd Erik Johansen, Tone Sjåheim,

INTRODUCTION:Idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD) are fibrotic ILDs with divergent disease populations. Little is known about health-related quality of life (HRQL) in SSc-ILD relative to IPF. METHODS:We used the Kings Brief Interstitial Lung Disease Questionnaire (K-BILD) to compare HRQL in a cross-sectional study of ... Read more >>

BMJ Open Respir Res (BMJ open respiratory research)
[2020, 7(1):]

Cited: 0 times

View full text PDF listing >>



Diabetes-specific dementia risk score (DSDRS) predicts cognitive performance in patients with type 2 diabetes at high cardio-renal risk.

Chloë Verhagen, Jolien Janssen, Lieza G Exalto, Esther van den Berg, Odd Erik Johansen, Geert Jan Biessels,

AIM:To investigate the relationship between the diabetes-specific dementia risk score (DSDRS) and concurrent and future cognitive impairment (CI) in type 2 diabetes (T2D). METHODS:DSDRS were calculated for participants with T2D aged ≥60 years from the CARMELINA-cognition substudy (ClinicalTrials.gov Identifier: NCT01897532). Cognitive assessment included Mini-Mental State Examination (MMSE) and a composite attention ... Read more >>

J Diabetes Complications (Journal of diabetes and its complications)
[2020, 34(10):107674]

Cited: 1 time

View full text PDF listing >>



MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D.

Silvio E Inzucchi, Melanie Davies, Kamlesh Khunti, Prabhav Trivedi, Jyothis T George, Isabella Zwiener, Odd Erik Johansen, Naveed Sattar,

AbstractSodium-glucose co-transporter-2 inhibitors (SGLT2i) are commonly used as 2nd-line therapy after metformin (MET) in patients with type 2 diabetes (T2D), and are now recommended in those with co-existing cardiovascular (CV) and/or chronic kidney disease (CKD). A better understanding of their clinical efficacy across the spectrum of cardio-metabolic characteristics may help ... Read more >>

J Endocr Soc (Journal of the Endocrine Society)
[2020, 4(Suppl 1):]

Cited: 0 times

View full text PDF listing >>



Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.

Vlado Perkovic, Robert Toto, Mark E Cooper, Johannes F E Mann, Julio Rosenstock, Darren K McGuire, Steven E Kahn, Nikolaus Marx, John H Alexander, Bernard Zinman, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Maximillian von Eynatten, Jyothis T George, Odd Erik Johansen, Christoph Wanner, ,

OBJECTIVE:Type 2 diabetes is a leading cause of kidney failure, but few outcome trials proactively enrolled individuals with chronic kidney disease (CKD). We performed secondary analyses of cardiovascular (CV) and kidney outcomes across baseline estimated glomerular filtration rate (eGFR) categories (≥60, 45 to <60, 30 to <45, and <30 mL/min/1.73 ... Read more >>

Diabetes Care (Diabetes care)
[2020, 43(8):1803-1812]

Cited: 0 times

View full text PDF listing >>



Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial.

Mark E Cooper, Julio Rosenstock, Takashi Kadowaki, Yutaka Seino, Christoph Wanner, Sven Schnaidt, Douglas Clark, Odd Erik Johansen, ,

AIMS:In CARMELINA®, linagliptin demonstrated cardiovascular and renal safety in patients with type 2 diabetes (T2D) with high renal and cardiovascular disease (CVD) risk. We investigated safety and efficacy of this dipeptidyl peptidase-4 inhibitor in older participants. MATERIALS AND METHODS:Subjects aged ≥18 years with T2D and established CVD with urinary albumin-to-creatinine ratio ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, 22(7):1062-1073]

Cited: 1 time

View full text PDF listing >>



Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.

David Fitchett, Silvio E Inzucchi, Christoph Wanner, Michaela Mattheus, Jyothis T George, Ola Vedin, Bernard Zinman, Odd Erik Johansen,

AIMS:Hypoglycaemia, in patients with Type 2 diabetes (T2D) is associated with an increased risk for cardiovascular (CV) events. In EMPA-REG OUTCOME, the sodium-glucose co-transporter-2 inhibitor empagliflozin reduced the risk of CV death by 38% and heart failure hospitalization (HHF) by 35%, while decreasing glycated haemoglobin (HbA1c) without increasing hypoglycaemia. We ... Read more >>

Eur Heart J (European heart journal)
[2020, 41(2):209-217]

Cited: 4 times

View full text PDF listing >>



Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.

Nobuya Inagaki, Wenying Yang, Hirotaka Watada, Linong Ji, Sven Schnaidt, Egon Pfarr, Tomoo Okamura, Odd Erik Johansen, Jyothis T George, Maximilian von Eynatten, Julio Rosenstock, Vlado Perkovic, Christoph Wanner, Mark E Cooper, John H Alexander, Issei Komuro, Masaomi Nangaku,

Objective:Linagliptin, a dipeptidyl peptidase-4 inhibitor, demonstrated cardiovascular and renal safety in type 2 diabetes mellitus (T2DM) patients with established cardiovascular disease (CVD) with albuminuria and/or kidney disease in the multinational CARMELINA® trial. We investigated the effects of linagliptin in Asian patients in CARMELINA®. Methods:T2DM patients with HbA1c 6.5-10.0% and established ... Read more >>

Diabetol Int (Diabetology international)
[2020, 11(2):129-141]

Cited: 1 time

View full text PDF listing >>



Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.

Julio Rosenstock, Steven E Kahn, Odd Erik Johansen, Bernard Zinman, Mark A Espeland, Hans J Woerle, Egon Pfarr, Annett Keller, Michaela Mattheus, David Baanstra, Thomas Meinicke, Jyothis T George, Maximilian von Eynatten, Darren K McGuire, Nikolaus Marx, ,

Importance:Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferiority, but it has not been tested against an active comparator. Objective:This trial assessed cardiovascular outcomes of linagliptin vs glimepiride (sulfonylurea) in patients with relatively early type 2 diabetes and ... Read more >>

JAMA (JAMA)
[2019, :]

Cited: 25 times

View full text PDF listing >>



Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial.

Geert Jan Biessels, Chloë Verhagen, Jolien Janssen, Esther van den Berg, Bernard Zinman, Julio Rosenstock, Jyothis T George, Anna Passera, Sven Schnaidt, Odd Erik Johansen, ,

OBJECTIVE:Type 2 diabetes is associated with cognitive dysfunction and an increased dementia risk, particularly in individuals with concomitant cardiovascular and/or kidney disease. Incretin therapies may modulate this risk via glycemic and nonglycemic pathways. We explored if the dipeptidyl peptidase 4 inhibitor linagliptin could prevent cognitive decline in people with type ... Read more >>

Diabetes Care (Diabetes care)
[2019, 42(10):1930-1938]

Cited: 5 times

View full text PDF listing >>



Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort.

Lan Ai Kieu Le, Ane Johannessen, Jon Andrew Hardie, Odd Erik Johansen, Amund Gulsvik, Bjørn Egil Vikse, Per Bakke,

Rationale:The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 is based on an ABCD assessment tool of symptoms and exacerbation history and grade 1-4 of airflow limitation severity, facilitating classification either into 4 groups (ABCD) or 16 groups (1A-4D). We aimed to compare the GOLD 2011, GOLD 2017 ABCD, ... Read more >>

Int J Chron Obstruct Pulmon Dis (International journal of chronic obstructive pulmonary disease)
[2019, 14:1639-1655]

Cited: 1 time

View full text PDF listing >>



Comparison of the associations between non-traditional and traditional indices of adiposity and cardiovascular mortality: an observational study of one million person-years of follow-up.

Anne Pernille Ofstad, Christine Sommer, Kåre I Birkeland, Marit Rokne Bjørgaas, Jon Michael Gran, Hanne Løvdal Gulseth, Odd Erik Johansen,

BACKGROUND/OBJECTIVE:The most widely used adiposity index, body mass index (BMI), is not optimal to evaluate cardiovascular (CV) risk associated with overweight and obesity. We aimed to explore the association between traditional and non-traditional adiposity indices and CV mortality, and compare their discriminative ability for CV death. METHODS:We studied participants (age ... Read more >>

Int J Obes (Lond) (International journal of obesity (2005))
[2019, 43(5):1082-1092]

Cited: 1 time

View full text PDF listing >>



Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes.

Onno N Groeneveld, Esther van den Berg, Odd Erik Johansen, Sven Schnaidt, Karin Hermansson, Bernard Zinman, Mark A Espeland, Geert Jan Biessels,

OBJECTIVE:Type 2 diabetes is associated with cognitive dysfunction, but the mechanisms are unknown. We assessed the relationships of biomarkers of oxidation, endothelial function and inflammation with cognition in participants of the CAROLINA® trial (CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes). METHODS:Baseline circulating biomarkers of oxidation (8-iso-prostaglandin ... Read more >>

Diab Vasc Dis Res (Diabetes & vascular disease research)
[2019, 16(6):577-581]

Cited: 1 time

View full text PDF listing >>



Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke.

Vladimer Darsalia, Odd Erik Johansen, Grazyna Lietzau, Thomas Nyström, Thomas Klein, Cesare Patrone,

Cerebral stroke is a leading cause of death and persistent disability of elderly in the world. Although stroke prevention by targeting several risk factors such as diabetes and hypertension has decreased the stroke incidence, the total number of strokes is increasing due to the population aging and new preventive therapies ... Read more >>

Front Neurol (Frontiers in neurology)
[2019, 10:493]

Cited: 3 times

View full text PDF listing >>



SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA

Steven Kahn, Vlado Perkovic, Odd Erik Johansen, Julio Rosenstock, Darren McGuire, Robert Toto, Marx Nikolaus, John Alexander, Bernard Zinman, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Jyothis George, Max von Eynatten, Mark Cooper, Christoph Wanner,

Abstract People with type 2 diabetes (T2D) with concomitant chronic kidney disease (CKD) and cardiovascular (CV) disease are at increased risk for recurrent CV events and hypoglycemia. Treatment of these individuals is clinically challenging, where the evidence-base for safety and efficacy of glucose lowering drugs is scarce, in particular in ... Read more >>

J Endocr Soc (Journal of the Endocrine Society)
[2019, 3(Suppl 1):]

Cited: 0 times

View full text PDF listing >>



Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation.

Satish Arora, Anne Pernille Ofstad, Geir R Ulimoen, Kåre I Birkeland, Knut Endresen, Lars Gullestad, Odd Erik Johansen,

AIMS:The prevalence of asymptomatic coronary artery disease (CAD) in type 2 diabetes (T2D) is unclear. We investigated the extent and prevalence of asymptomatic CAD in T2D patients by utilizing invasive coronary angiography (ICA) and intravascular ultrasound (IVUS), and whether CAD progression, evaluated by ICA, could be modulated with a multi-intervention ... Read more >>

Cardiovasc Diabetol (Cardiovascular diabetology)
[2019, 18(1):26]

Cited: 1 time

View full text PDF listing >>



Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

David Fitchett, Silvio E Inzucchi, Christopher P Cannon, Darren K McGuire, Benjamin M Scirica, Odd Erik Johansen, Steven Sambevski, Stefan Kaspers, Egon Pfarr, Jyothis T George, Bernard Zinman,

BACKGROUND:In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease, in comparison with placebo, empagliflozin reduced the risks of 3-point major adverse cardiovascular events (3-point MACE), cardiovascular and all-cause death, and ... Read more >>

Circulation (Circulation)
[2019, 139(11):1384-1395]

Cited: 20 times

View full text PDF listing >>



Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

Darren K McGuire, John H Alexander, Odd Erik Johansen, Vlado Perkovic, Julio Rosenstock, Mark E Cooper, Christoph Wanner, Steven E Kahn, Robert D Toto, Bernard Zinman, David Baanstra, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Jyothis T George, Maximilian von Eynatten, Nikolaus Marx, ,

BACKGROUND:Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease. Some but not all dipeptidyl peptidase-4 inhibitors have been associated with increased HF risk. We performed secondary analyses of HF and related outcomes with the dipeptidyl ... Read more >>

Circulation (Circulation)
[2019, 139(3):351-361]

Cited: 23 times

View full text PDF listing >>



FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.

Darren K McGuire, Nikolaus Marx, Odd Erik Johansen, Silvio E Inzucchi, Julio Rosenstock, Jyothis T George,

In 2008, the US Food and Drug Administration (FDA) issued a guidance to industry statement concerning evaluation of the cardiovascular (CV) safety of new antihyperglycaemic therapies for type 2 diabetes. Fifteen CV outcome trials assessing three novel classes of antihyperglycaemic therapies, DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors, were ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2019, 21(5):1073-1078]

Cited: 5 times

View full text PDF listing >>



HbA1c, Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy.

Jolien Janssen, Esther van den Berg, Bernard Zinman, Mark A Espeland, Stefan L C Geijselaers, Michaela Mattheus, Odd Erik Johansen, Geert Jan Biessels,

Diabetes Care (Diabetes care)
[2019, 42(1):e1-e3]

Cited: 0 times

View full text PDF listing >>



Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner, Bernard Zinman, Hans Juergen Woerle, David Baanstra, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Jyothis T George, Maximilian von Eynatten, Darren K McGuire, ,

Importance:Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. Objective:To evaluate the effect of linagliptin, a selective DPP-4 inhibitor, on CV ... Read more >>

JAMA (JAMA)
[2019, 321(1):69-79]

Cited: 106 times

View full text PDF listing >>



Author's response to: letter to the editor.

Anne Pernille Ofstad, Dan Atar, Lars Gullestad, Gisle Langslet, Odd Erik Johansen,

Heart Fail Rev (Heart failure reviews)
[2018, 23(5):819]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.4156 s